-
Heart Failure Drug Natrecor Fails Efficacy Part Of “Off-label” Use Study
Safety Profile Of Natrecor Continues To Be Subject Of Controversy And Debate (Posted by Tom Lamb at DrugInjuryWatch.com) The results of a large study for Johnson & Johnson’s heart failure drug Natrecor failed to…
-
Sanofi-Aventis Sends “Dear Doctor” Letter Regarding Antibiotic Ketek In Late March 2007
The Letter Concerns Black-Box Warning, Prescribing Changes, And Patient Medication Guide Announced Back In Mid-February 2007 (Posted by Tom Lamb at DrugInjuryWatch.com) On March 26, 2007 the FDA announced that a so-called "Dear Doctor"…
-
March 2007 GAO Testimony On The Effectiveness Of FDA’s Postmarket Drug Safety Monitoring
FDA’s Current Initiatives May Or May Not Address Past Shortcomings — Too Early To Tell, Still (Posted by Tom Lamb at DrugInjuryWatch.com) In March 2007 Marcia Crosse, a representative of the U.S. Government Accountability…
-
FDA Issues March 2007 Safety Alert For Pfizer Antibiotic Zyvox
Study Suggests That Higher Chance Of Death Is Related To The Type Of Organism Causing A Patient’s Infection (Posted by Tom Lamb at DrugInjuryWatch.com) On March 16, 2007 the FDA issued a safety alert…
-
Parkinson’s Drug Permax Increases Risk of Cardiac Valve Regurgitation With Long-term Use
Authors of March 2007 Report Advise That Permax Use Should Be Stopped If Possible Due To Risk of Valvulopathy, Or Heart Valve Damage (Posted by Tom Lamb at DrugInjuryWatch.com) A new study published in…
-
Procrit, Epogen, And Aranesp: New “Black Box” Warnings Only First Part Of FDA’s Safety Re-evaluation
Popular Anemia Drugs Have Increased Risk Of Death, Blood Clots, Strokes, And Heart Attacks, Especially In Context Of Off-label Prescribing And Use (Posted by Tom Lamb at DrugInjuryWatch.com) On March 9, 2007 the FDA…
